F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Statements from the Taormina expert meeting on occult hepatitis B virus infection.
Giovanni Raimondo,Jean-Pierre Allain,Maurizia Rossana Brunetto,Marie Annick Buendia,Ding-Shinn Chen,Massimo Colombo,Antonio Craxì,Francesco Donato,Carlo Ferrari,Giovanni Battista Gaeta,Wolfram H. Gerlich,Massimo Levrero,Stephen Locarnini,Thomas I. Michalak,Mario U. Mondelli,Jean-Michel Pawlotsky,Teresa Pollicino,Daniele Prati,Massimo Puoti,Didier Samuel,Daniel Shouval,Antonina Smedile,Giovanni Squadrito,Christian Trepo,Erica Villa,Hans Will,Alessandro Zanetti,Fabien Zoulim +27 more
TL;DR: Giovanni Raimondo*, Jean-Pierre Allain, Maurizia R. Brunetto, Marie-Annick Buendia, Ding-Shinn Chen, Massimo Colombo, Antonio Craxi, Francesco Donato, Carlo Ferrari, Giovanni B. Gaeta, Wolfram H. Gerlich,Massimo Levrero, Stephen Locarnini, Thomas Michalak, Mario U. Zanetti, Fabien Zoulim
Journal ArticleDOI
Hepatitis B virus resistance to nucleos(t)ide analogues.
TL;DR: It is important to continue basic research into HBV replication and pathogenic mechanisms to identify new therapeutic targets, develop novel antiviral agents, design combination therapies that prevent drug resistance, and decrease the incidence of complications of CHB.
Journal ArticleDOI
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
Anna S. Lok,Fabien Zoulim,Stephen Locarnini,Angeline Bartholomeusz,Marc G. Ghany,Jean-Michel Pawlotsky,Yun-Fan Liaw,Masashi Mizokami,Carla Kuiken +8 more
TL;DR: There is a need to standardize nomenclature relating to hepatitis B antiviral resistance, and to define genotypic, phenotypesic, and clinical resistance to NA therapy.
Journal ArticleDOI
Woodchuck hepatitis virus X protein is required for viral infection in vivo.
TL;DR: Results indicate that the X gene of the hepadnaviruses plays a major role in viral replication in vivo.
Journal ArticleDOI
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890
Christophe Hézode,Hélène Fontaine,Céline Dorival,Dominique Larrey,Fabien Zoulim,Valérie Canva,Victor de Lédinghen,Thierry Poynard,Didier Samuel,Marc Bourlière,Jean-Pierre Zarski,J.-J. Raabe,Laurent Alric,Patrick Marcellin,Ghassan Riachi,Pierre-Henri Bernard,Véronique Loustaud-Ratti,Sophie Metivier,Albert Tran,Lawrence Serfaty,Armand Abergel,Xavier Causse,Vincent Di Martino,Dominique Guyader,Damien Lucidarme,Véronique Grando-Lemaire,Patrick Hillon,Cyrille Feray,Thong Dao,Patrice Cacoub,Isabelle Rosa,Pierre Attali,Ventzislava Petrov-Sanchez,Yoann Barthe,Jean-Michel Pawlotsky,Stanislas Pol,Fabrice Carrat,Jean-Pierre Bronowicki +37 more
TL;DR: The safety profile was poor and patients with platelet count ≤ 100,000/mm(3) and serum albumin <35 g/L should not be treated with the triple therapy, and the on-treatment virological response was high.